$HALB Halberd’s Successful Completion of Samplin
Post# of 35498
(Total Views: 94)
Posted On: 08/22/2023 8:33:46 AM
$HALB Halberd’s Successful Completion of Sampling Phase Marks Major Milestone for Project at Mississippi State University (MSU)
https://www.accesswire.com/775802/Halberds-Su...ersity-MSU
Novel Nasal Spray for Traumatic Brain Injury Effects Poised to Demonstrate Efficacy in Patent-Pending Product
JACKSON CENTER, PA / ACCESSWIRE / August 22, 2023 / Halberd Corporation (OTC PINK:HALB) announced Mississippi State University (MSU) has finalized the collection of tissue samples from a quantity of the planned test subjects. This enables MSU to proceed with its pre-clinical model to study endpoints for Halberd's groundbreaking patent-pending nasal spray's ability to mitigate the effects of traumatic brain injury (TBI). The analysis of these tissue samples can now proceed to examine and quantify the presence of certain markers related to brain damage and to assess the effectiveness of the nasal spray treatment. The nasal spray is designed to eliminate the otherwise inevitable and irreversible negative effects of TBI by directly targeting the associated antigens in cerebrospinal fluid (CSF).
Halberd's nasal spray employs a patent-pending blend of three active ingredients designed to timely address and block the excess production of certain identified inflammatory cytokines and neurotransmitters triggered by head trauma. Excess quantities of these elements are associated with irreversible brain injury. The testing at MSU will evaluate the importance of the timely application of Halberd's nasal spray within hours of a traumatic brain injury to mitigate the otherwise inevitable long-term neurodegeneraton often leading to not just TBI, but also to Alzheimer's Disease, Parkinson's Disease, Epileptic seizures, PTSD, etc.
Halberd's early treatment nasal spray product has the potential for wide acceptance by contact sports participants, first responders, trauma centers and the military. Following successful completion of these pre-clinical tests, Halberd intends to immediately seek expeditious approval of the treatment by the FDA and other regulatory bodies throughout the world to enable sale and distribution within the United States as well as other potential world markets. As previously reported, Halberd has already engaged experts for this pursuit with the FDA.
To get the latest news on Halberd's exciting developments, subscribe by submitting this.
(https://halberdcorporation.com/contact-us/)
https://www.accesswire.com/775802/Halberds-Su...ersity-MSU
Novel Nasal Spray for Traumatic Brain Injury Effects Poised to Demonstrate Efficacy in Patent-Pending Product
JACKSON CENTER, PA / ACCESSWIRE / August 22, 2023 / Halberd Corporation (OTC PINK:HALB) announced Mississippi State University (MSU) has finalized the collection of tissue samples from a quantity of the planned test subjects. This enables MSU to proceed with its pre-clinical model to study endpoints for Halberd's groundbreaking patent-pending nasal spray's ability to mitigate the effects of traumatic brain injury (TBI). The analysis of these tissue samples can now proceed to examine and quantify the presence of certain markers related to brain damage and to assess the effectiveness of the nasal spray treatment. The nasal spray is designed to eliminate the otherwise inevitable and irreversible negative effects of TBI by directly targeting the associated antigens in cerebrospinal fluid (CSF).
Halberd's nasal spray employs a patent-pending blend of three active ingredients designed to timely address and block the excess production of certain identified inflammatory cytokines and neurotransmitters triggered by head trauma. Excess quantities of these elements are associated with irreversible brain injury. The testing at MSU will evaluate the importance of the timely application of Halberd's nasal spray within hours of a traumatic brain injury to mitigate the otherwise inevitable long-term neurodegeneraton often leading to not just TBI, but also to Alzheimer's Disease, Parkinson's Disease, Epileptic seizures, PTSD, etc.
Halberd's early treatment nasal spray product has the potential for wide acceptance by contact sports participants, first responders, trauma centers and the military. Following successful completion of these pre-clinical tests, Halberd intends to immediately seek expeditious approval of the treatment by the FDA and other regulatory bodies throughout the world to enable sale and distribution within the United States as well as other potential world markets. As previously reported, Halberd has already engaged experts for this pursuit with the FDA.
To get the latest news on Halberd's exciting developments, subscribe by submitting this.
(https://halberdcorporation.com/contact-us/)
(0)
(0)Scroll down for more posts ▼